NCT02980523View on ClinicalTrials.gov

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

PHASE2CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

May 31, 2017

Conditions

Bacterial Conjunctivitis

Interventions

DRUG

PRO-157

PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution

DRUG

Vigamox

Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution

DRUG

Zymar®

Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution

DRUG

Lagricel Ofteno®

Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution

Trial Locations (1)

44690

"Unidad Medica Grupo Pediátrico", Guadalajara

All Listed Sponsors

lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT02980523 - Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) | Biotech Hunter | Biotech Hunter